🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Amazing view of San Diego tonight from 15 stories up at #ASH24

Dr. Fenske Tim Fenske presenting this important late breaking abstract Nirav Shah Mehdi Hamadani, MD MCW Cancer Center ASH #ASH2024

WOW- practice changing MCL trial showing no benefit of autoHCT in uMRD MCL in first remission. Bravo ECOG team. Tim Fenske #ASH24

CONGRESS #ASH24 | LBA Tim Fenske, Medical College of Wisconsin presented an initial report from the phase III ECOG-ACRIN trial. The 3-yr OS for Arms A and B were 86.2% and 84.8% in treated as assigned pts, and 81.9% and 85.1% for Arms C and D, respectively. MCL pts in first CR with uMRD6 did

LIVE from the late breaking abstract session at #ASH24: Timothy Fenske, MD (Tim Fenske) from Medical College of Wisconsin shares an initial report from the ECOG-ACRIM EA4151 phase 3 randomized trial. ➡️In this initial analysis, in the era of highly effective induction and maintenance

7. Use of IVIG for BCMA bispecific antibodies: - Primary prophylactic IVIG before any documented infection - OS seen (likely because of improved outcomes from infections) - Should now be part of all BCMA bispecifics 8/10

Proud of my friend and colleague ⁦Tim Fenske⁩ for delivering an excellent LBA #ash 24 ⁦MCW Cancer Center⁩ ⁦ASH⁩ ! Great to have LBA in 2 consecutive years from our group - Cart 4 at ASCO23 and MCL at ASH24

Autologous hematopoietic stem cell transplantation did not benefit adults with mantle cell lymphoma in first complete remission after induction, according to study data at #ASH24. Healio spoke with Tim Fenske of Medical College of Wisconsin about the data. #Lymphoma healio.com/news/hematolog…

In a phase 3 trial, ASCT did not improve survival outcomes in patients with MCL who had an MRD-negative CR after induction. Presented at #ASH24 by Tim Fenske from Medical College of Wisconsin. #lymsm cancertherapyadvisor.com/reports/asct-d…

Jimmy Carter‘s presidency is extraordinarily underrated. But this is a good time to tell my favorite personal story. I was an advisor to the Carter Baker commission on election reform. At one of the meetings, President Carter asked if I would have lunch with him. 1/

Milwaukee’s version of National Lampoon Christmas Vacation 😊

Our new BMT CTN 1703 analysis busts a few myths: - QOL improved with ptCY - 🩸Cystitis not worse - 2yr GRFS superior 42% vs 29%, p=0.001 - ptCY relapse NOT higher Shernan Holtan MD Javier Bolaños Meade, MD TY to Mike Martens for elegant analysis #GvHD #alloHCT #BMT ascopubs.org/doi/10.1200/JC…

I'm concerned that the recent STAT piece re: decline of #BMT by Angus Rohan Chen could be misleading to the public. Adding some context for consideration in the thread 🧵below: statnews.com/2024/12/24/bon…

Officially a resident of Texas now 🤠

🚨🚨Join us in Chicago, April 4 & 5 for the 22nd Annual International Ultmann Chicago Lymphoma Symposium (bioascend.com/chicago-lympho…). ➡️➡️In addition to "Mini-Symposiums" on #DLBCL, Mantle cell, #HRQL & #Genomic Diagnostics, we're thrilled to have Dr Nancy Bartlett as our Keynote!

Just out Blood Journal : Outcome of #CART therapy for #burkitt #lymphoma. Another great internatioal collaboration led by Laura Samples, MD Fred Hutch Cancer Center UW Medicine Newsroom ashpublications.org/blood/article-…

🎸🎼🎹🥁Hear the walk-up songs for the mini-symposium on #mantlecell lymphoma. We were happy to invite City of Hope Dr Tycel Phillips, Hackensack Meridian Dr Lori Leslie & Sarah Cannon Docs Tim Fenske. 🧭🧭 Many varied options for untreated & relapsed disease! Soni Smith MD #IUCLS2025

Correspondence: Glofitamab with Polatuzumab Vedotin in Refractory Burkitt’s Lymphoma nej.md/4lS7kfe #Hematology

Editing is too funny 😂

DISEASES ERADICATED OR DECIMATED BY SCIENCE: 1. Chickenpox 2. Diphtheria 3. Measles 4. Pertussis 5. Pneumococcal Infection 6. Polio 7. Tetanus 8. Typhoid 9. Yellow Fever 10. Smallpox DISEASES ERADICATED OR DECIMATED BY RFK JR. OR PRAYER: 1. 2. 3. 4. 5. 6. 7. 8. 9. 10.